A study of the impact of leg ulcers on quality of life: Financial, social, and psychologic implications

Phillips, Tania J.; Stanton, Babette-Ann; Provan, Andrea; Lew, Robert A.

doi:10.1016/s0190-9622(94)70134-2

Cited by 467 publications

(355 citation statements)

References 18 publications

Supporting

Mentioning

324

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] Identifying and determining the exact functions of the numerous growth factors and molecules that regulate or modulate growth factor-induced signaling in wounds, particularly those which contribute to the re-epithelialization The rise in metabolic diseases, such as type-2 diabetes, has led to a similar increase in comorbidities such as chronic leg and foot ulcers, which together affect more than 2.5 million Americans. 5 …”

Section: Translational Relevancementioning

confidence: 99%

The Roles of Growth Factors in Keratinocyte Migration

Seeger

Paller

2015

Advances in Wound Care

170

126

View full text Add to dashboard Cite

Section: Translational Relevancementioning

confidence: 99%

The Roles of Growth Factors in Keratinocyte Migration

Seeger

Paller

2015

Advances in Wound Care

170

126

View full text Add to dashboard Cite

“…17 Difficult-to-heal wounds affect tens of millions of people worldwide. In the U.S., studies have shown that approximately 2.5 million people have venous ulcers, 18,19 while pressure ulcers afflict an additional 1.3-3 million people, 20 including an estimated 10%-18% of those in acute care and up to 28% of those in extended care facilities. 21 Approximately 15% of the 16 million U.S. adults with diabetes will develop serious foot ulcers within their lifetime.…”

Section: Introductionmentioning

confidence: 99%

Optimizing Wound Bed Preparation With Collagenase Enzymatic Debridement

McCallon

Weir

Lantis

2014

Journal of the American College of Clinical Wound Specialists

View full text Add to dashboard Cite

Difficult-to-heal and chronic wounds affect tens of millions of people worldwide. In the U.S. alone, the direct cost for their treatment exceeds $25 billion. Yet despite advances in wound research and treatment that have markedly improved patient care, wound healing is often delayed for weeks or months. For venous and diabetic ulcers, complete wound closure is achieved in as few as 25%-50% of chronic or hard-to-heal wounds. Wound bed preparation and the consistent application of appropriate and effective debridement techniques are recommended for the optimized treatment of chronic wounds. The TIME paradigm (Tissue, Inflammation/infection, Moisture balance and Edge of wound) provides a model to remove barriers to healing and optimize the healing process. While we often think of debridement as an episodic event that occurs in specific care giver/patient interface. There is the possibility of a maintenance debridement in which the chronic application of a medication can assist in both the macroscopic and microscopic debridement of a wound. We review the various debridement therapies available to clinicians in the United States, and explore the characteristics and capabilities of clostridial collagenase ointment (CCO), a type of enzymatic debridement, that potentially allows for epithelialization while debriding. It appears that in the case of CCO it may exert this influences by removal of the necrotic plug while promoting granulation and sustaining epithelialization. It is also easily combined with other methods of debridement, is selective to necrotic tissue, and has been safely used in various populations. We review the body of evidence has indicated that this concept of maintenance debridement, especially when combined episodic debridement may add a cost an efficacious, safe and cost-effective choice for debridement of cutaneous ulcers and burn wounds and it will likely play an expanding role in all phases of wound bed preparation.

show abstract

“…Although the overall prevalence is relatively low, the refractory nature of these ulcers increase the risk of morbidity and mortality, and have a significant impact on patient quality of life [5,7]. The financial burden of venous ulcers is estimated to be $2 billion per year in the United States [9].…”

Section: Introductionmentioning

confidence: 99%